The DOI matches its Crossref record; 339 of the 339 references it cites were found in a registry or an index.
Challenges and Opportunities in Cancer Drug Resistance
Abstract
There has been huge progress in the discovery of targeted cancer therapies in recent years. However, even for the most successful and impactful cancer drugs which have been approved, both innate and acquired mechanisms of resistance are commonplace. These emerging mechanisms of resistance have been studied intensively, which has enabled drug discovery scientists to learn how it may be possible to overcome such resistance in subsequent generations of treatments. In some cases, novel drug candidates have been able to supersede previously approved agents; in other cases they have been used sequentially or in combinations with existing treatments. This review summarizes the current field in terms of the challenges and opportunities that cancer resistance presents to drug discovery scientists, with a focus on small molecule therapeutics. As part of this review, common themes and approaches have been identified which have been utilized to successfully target emerging mechanisms of resistance. This includes the increase in target potency and selectivity, alternative chemical scaffolds, change of mechanism of action (covalents, PROTACs), increases in blood-brain barrier permeability (BBBP), and the targeting of allosteric pockets. Finally, wider approaches are covered such as monoclonal antibodies (mAbs), bispecific antibodies, antibody drug conjugates (ADCs), and combination therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–339 of 339
McDonnell, D. P., Wardell, S. E., & Norris, J. D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00760 · Cited by 178
Armstrong, B. K., Kricker, A., & English, D. R. (1997) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.1997.tb01000.x · Cited by 178
Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer
Nurwidya, F., Takahashi, F., Murakami, A., & Takahashi, K. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.3.151 · Cited by 177
Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma
Grillo-Lopez, A., White, C., Dallaire, B., Varns, C., Shen, C., Wei, A., Leonard, J., McClure, A., Weaver, R., Cairelli, S., et al. (2000) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201003379059 · Cited by 176
Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Bahcall, M., Sim, T., Paweletz, C. P., Patel, J. D., Alden, R. S., Kuang, Y., Sacher, A. G., Kim, N. D., Lydon, C. A., Awad, M. M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0686 · Cited by 173
New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome
Wilson, L. J., Linley, A., Hammond, D. E., Hood, F. E., Coulson, J. M., MacEwan, D. J., Ross, S. J., Slupsky, J. R., Smith, P. D., Eyers, P. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2291 · Cited by 172
Self-citationAmino acids: Chemistry, functionality and selected non-enzymatic post-translational modifications
Bischoff, R., & Schlüter, H. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.01.041 · Cited by 170
Engelhardt, H., Böse, D., Petronczki, M. P., Scharn, D., Bader, G., Baum, A., Bergner, A., Chong, E., Döbel, S., Egger, G., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01169 · Cited by 169
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
Reiff, S. D., Mantel, R., Smith, L. L., Greene, J. T., Muhowski, E. M., Fabian, C. A., Goettl, V. M., Tran, M., Harrington, B. K., Rogers, K. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1409 · Cited by 165
Kinoshita, K., Asoh, K., Furuichi, N., Ito, T., Kawada, H., Hara, S., Ohwada, J., Miyagi, T., Kobayashi, T., Takanashi, K., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.021 · Cited by 164
Moschos, S. J., Sullivan, R. J., Hwu, W., Ramanathan, R. K., Adjei, A. A., Fong, P. C. C., Shapira‐Frommer, R., Tawbi, H. A.-H., Rubino, J., Rush, T. S., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.92352 · Cited by 163
Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Portman, N., Alexandrou, S., Carson, E., Wang, S., Lim, E., & Caldon, C. E. (2019) · Endocrine-Related Cancer · doi:10.1530/erc-18-0317 · Cited by 163
Deshaies, R. J. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1887 · Cited by 162
KRAS and BRAF: drug targets and predictive biomarkers
Vakiani, E., & Solit, D. B. (2011) · The Journal of Pathology · doi:10.1002/path.2796 · Cited by 162
Sampath, D., Cortes, J., Estrov, Z., Du, M., Shi, Z., Andreeff, M., Gandhi, V., & Plunkett, W. (2005) · Blood · doi:10.1182/blood-2005-08-3351 · Cited by 160
Nilotinib: A Novel, Selective Tyrosine Kinase Inhibitor
Blay, J., & von Mehren, M. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.016 · Cited by 159
Garner, A. P., Gozgit, J. M., Anjum, R., Vodala, S., Schrock, A., Zhou, T., Serrano, C., Eilers, G., Zhu, M., Ketzer, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1397 · Cited by 158
Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies
Huck, B. R., Kötzner, L., & Urbahns, K. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707816 · Cited by 154
Gottesman, M. M., & Pastan, I. H. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv222 · Cited by 153
Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
Kancha, R. K., von Bubnoff, N. C. C., Bartosch, N., Peschel, C., Engh, R. A., & Duyster, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026760 · Cited by 152
Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy
Baran, N., & Konopleva, M. Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0895 · Cited by 149
Sun, X., Bao, J., & Shao, Y. (2016) · Scientific Reports · doi:10.1038/srep22498 · Cited by 147
First targeted protein degrader hits the clinic
Mullard, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00043-6 · Cited by 146
Yun, J., Hong, M. H., Kim, S., Park, C.-W., Kim, S., Yun, M. R., Kang, H. N., Pyo, K., Lee, S. S., Koh, J. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2906 · Cited by 146
Mathematical modeling and computational prediction of cancer drug resistance
Sun, X., & Hu, B. X. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx065 · Cited by 143
Overcoming resistance to BRAF inhibitors
Arozarena, I., & Wellbrock, C. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.09 · Cited by 142
Sepúlveda-Sánchez, J. M., Salgado, M. Á. V., Balañá, C., Gil‐Gil, M., Reynés, G., Gallego, O. S., Martinez‐García, M., Vicente, E., Quindós, M., Luque, R., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox105 · Cited by 139
Tria, G. S., Abrams, T. J., Baird, J., Burks, H. E., Firestone, B., Gaither, L. A., Hamann, L. G., He, G., Kirby, C. A., Kim, S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01682 · Cited by 137
Bivalent Ligands for Protein Degradation in Drug Discovery
Scheepstra, M., Hekking, K. F. W., Hijfte, L. V., & Folmer, R. H. A. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.01.006 · Cited by 134
Aromatase Inhibitors in Breast Cancer: An Overview
Altundağ, K., & Ibrahim, N. K. (2006) · The Oncologist · doi:10.1634/theoncologist.11-6-553 · Cited by 133
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
Cho, Y. S., Levell, J. R., Liu, G., Caferro, T. R., Sutton, J. C., Shafer, C. M., Costales, A., Manning, J. R., Zhao, Q. L., Sendzik, M., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00342 · Cited by 127
Chaturvedi, A., Herbst, L., Pusch, S., Klett, L. C., Goparaju, R., Stichel, D., Kaulfuß, S., Panknin, O., Zimmermann, K. C., Toschi, L., et al. (2017) · Leukemia · doi:10.1038/leu.2017.46 · Cited by 125
The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
Preković, S., van Royen, M. E., Voet, A. R. D., Geverts, B., Houtman, R., Melchers, D., Zhang, K. Y. J., den Broeck, T. V., Smeets, E., Spans, L., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0892 · Cited by 122
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Griffin, M., Scotto, D., Josephs, D. H., Mele, S., Crescioli, S., Bax, H. J., Pellizzari, G., Wynne, M. D., Nakamura, M., Hoffmann, R. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19836 · Cited by 122
In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data
Celebi, R., Bear Don’t Walk, O., Movva, R., Alpsoy, S., & Dumontier, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-45236-6 · Cited by 120
Selective estrogen receptor modulators (SERMs): A review of clinical data
Mirkin, S., & Pickar, J. H. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.10.010 · Cited by 120
Floc'h, N., Martin, M. J., Riess, J. W., Orme, J. P., Staniszewska, A. D., Ménard, L., Cuomo, M. E., O'Neill, D. J., Ward, R. A., Finlay, M. R. V., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0758 · Cited by 115
Self-citationBhagwat, S. V., McMillen, W. T., Cai, S., Zhao, B., Whitesell, M., Shen, W., Kindler, L. J., Flack, R. S., Wu, W., Anderson, B. D., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0183 · Cited by 112
Hanker, A. B., Brewer, M. R., Sheehan, J. H., Koch, J. P., Sliwoski, G. R., Nagy, R. J., Lanman, R. B., Berger, M. F., Hyman, D. M., Solit, D. B., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1431 · Cited by 109
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases
Yang, Z., Guo, Q., Wang, Y., Chen, K., Zhang, L., Cheng, Z., Xu, Y., Yin, X., Bai, Y., Rabbie, S. C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0976 · Cited by 107
Shibata, N., Miyamoto, N., Nagai, K., Shimokawa, K., Sameshima, T., Ohoka, N., Hattori, T., Imaeda, Y., Nara, H., Cho, N., et al. (2017) · Cancer Science · doi:10.1111/cas.13284 · Cited by 106
Lovera, S., Sutto, L., Boubeva, R., Scapozza, L., Dölker, N., & Gervasio, F. L. (2012) · Journal of the American Chemical Society · doi:10.1021/ja210751t · Cited by 104
Rangachari, D., To, C., Shpilsky, J. E., VanderLaan, P. A., Kobayashi, S. S., Mushajiang, M., Lau, C. J., Paweletz, C. P., Oxnard, G. R., Janne, P. A., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.016 · Cited by 104
Approaches to modernize the combination drug development paradigm
Day, D., & Siu, L. L. (2016) · Genome Medicine · doi:10.1186/s13073-016-0369-x · Cited by 103
Johnson, A. J., Yeh, Y.-Y., Smith, L. L., Wagner, A. J., Hessler, J. D., Gupta, S. V., Flynn, J. M., Jones, J. A., Zhang, X., Bannerji, R., et al. (2012) · Leukemia · doi:10.1038/leu.2012.144 · Cited by 102
Prediction of Cancer Drug Resistance and Implications for Personalized Medicine
Volm, M., & Efferth, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00282 · Cited by 102
Li, K., Yang, M., Liang, N., & Li, S. (2017) · Oncology Reports · doi:10.3892/or.2017.5409 · Cited by 100
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors
Kalra, S., Joshi, G., Munshi, A., & Kumar, R. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.071 · Cited by 98
Solomon, B., Wilner, K. D., & Shaw, A. T. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.200 · Cited by 97
Grugan, K. D., Dorn, K., Jarantow, S. W., Bushey, B. S., Pardinas, J. R., Laquerre, S. G., Moores, S. L., & Chiu, M. L. (2016) · mAbs · doi:10.1080/19420862.2016.1249079 · Cited by 96
Lelais, G., Epple, R., Marsilje, T. H., Long, Y. O., McNeill, M., Chen, B., Lu, W., Anumolu, J., Badiger, S., Bursulaya, B., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01985 · Cited by 95
Callegari, D., Ranaghan, K. E., Woods, C. J., Minari, R., Tiseo, M., Mor, M., Mulholland, A. J., & Lodola, A. (2018) · Chemical Science · doi:10.1039/c7sc04761d · Cited by 95
Hauser, K., Negron, C., Albanese, S. K., Ray, S. S., Steinbrecher, T. B., Abel, R., Chodera, J. D., & Wang, L. (2018) · Communications Biology · doi:10.1038/s42003-018-0075-x · Cited by 93
Greene, J. M., Gevertz, J. L., & Sontag, E. D. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.18.00087 · Cited by 91
Kalous, O., Conklin, D. F., Desai, A. J., O’Brien, N. A., Ginther, C., Anderson, L. A., Cohen, D. J., Britten, C. D., Taylor, I., Christensen, J. G., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0730 · Cited by 90
TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Hasako, S., Terasaka, M., Abe, N., Uno, T., Ohsawa, H., Hashimoto, A., Fujita, R., Tanaka, K., Okayama, T., Wadhwa, R., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1206 · Cited by 88
Avizienyte, E., Ward, R. A., & Garner, A. P. (2008) · Biochemical Journal · doi:10.1042/bj20080728 · Cited by 88
Self-citationXu, X., Mao, L., Xu, W., Tang, W., Zhang, X., Xi, B., Xu, R., Fang, X., Liu, J., Fang, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0281 · Cited by 87
Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism
Joyce, H., McCann, A., CLYNES, M. M., & Larkin, A. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1028356 · Cited by 86
Meric‐Bernstam, F., Beeram, M., Mayordomo, J. I., Hanna, D. L., Ajani, J. A., Murphy, M. B., Murthy, R. K., Piha-Paul, S. A., Bauer, T. M., Bendell, J. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.2500 · Cited by 86
C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?
Grabe, T., Lategahn, J., & Rauh, D. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00314 · Cited by 84
Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR
Petros, A. M., Huth, J. R., Oost, T. K., Park, C., Ding, H., Wang, X., Zhang, H., Nimmer, P. M., Mendoza, R. R., Sun, C. C., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.033 · Cited by 81
Ward, R. A., Anderton, M. J., Bethel, P. A., Breed, J., Cook, C., Davies, E. J., Dobson, A. P., Dong, Z., Fairley, G., Farrington, P. M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01295 · Cited by 81
Self-citationDefects in the apoptotic machinery of cancer cells: role in drug resistance
Zhivotovsky, B., & Orrenius, S. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00130-x · Cited by 80
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas
Aalipour, A., & Advani, R. H. (2013) · British Journal of Haematology · doi:10.1111/bjh.12573 · Cited by 79
Udagawa, H., Hasako, S., Ohashi, A., Fujioka, R., Hakozaki, Y., Shibuya, M., Abe, N., Komori, T., Haruma, T., Terasaka, M., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0419 · Cited by 79
Liu, Y., Li, Y., Ou, Q., Wu, X., Wang, X., Shao, Y. W., & Ying, J. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.015 · Cited by 78
Lampson, B. L., & Brown, J. R. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1435268 · Cited by 77
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2
Ma, R., & Yun, C. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.08.068 · Cited by 77
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
Passaro, A., Guerini‐Rocco, E., Pochesci, A., Vacirca, D., Spitaleri, G., Catania, C., Rappa, A., Barberis, M. C. P., & de Marinis, F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.003 · Cited by 76
In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
Rosa, R., Monteleone, F., Zambrano, N., & Bianco, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113209990226 · Cited by 73
Wang, Y., Gallagher, E., Jorgensen, C., Troendle, E. P., Hu, D., Searson, P. C., & Ulmschneider, M. B. (2019) · Scientific Reports · doi:10.1038/s41598-019-42272-0 · Cited by 73
Urban, D. J., Martinez, N. J., Davis, M. I., Brimacombe, K. R., Cheff, D. M., Lee, T. D., Henderson, M. J., Titus, S. A., Pragani, R., Rohde, J. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12630-x · Cited by 73
Bardia, A., Aftimos, P. G., Bihani, T., Anderson-Villaluz, A. T., Jung, J., Conlan, M. G., & Kaklamani, V. (2019) · Future Oncology · doi:10.2217/fon-2019-0370 · Cited by 72
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
Baraibar, I., Mezquita, L., Bazo, I. G., & Planchard, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102906 · Cited by 72
Cho, B. C., Drilon, A. E. D. C., Doebele, R. C., Kim, D., Lin, J. J., Lee, J., Ahn, M., Zhu, V. W., Ejadi, S., Camidge, D. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9011 · Cited by 70
Human Tumor Xenografts: The Good, the Bad, and the Ugly
Morgan, R. A. (2012) · Molecular Therapy · doi:10.1038/mt.2012.73 · Cited by 69
Nardone, A., Weir, H. M., Delpuech, O., Brown, H., Angelis, C. D., Cataldo, M. L., Fu, X., Shea, M. J., Mitchell, T., Veeraraghavan, J., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0354-9 · Cited by 68
Hanan, E. J., Eigenbrot, C. W., Bryan, M. C., Burdick, D. J., Chan, B. K., Chen, Y., Dotson, J., Heald, R. A., Jackson, P. S., La, H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501578n · Cited by 67
cMET Exon 14 Skipping: From the Structure to the Clinic
Steen, N. V. D., Giovannetti, E., Pauwels, P., Peters, G. J., Hong, D. S., Cappuzzo, F., Hirsch, F. R., & Rolfo, C. D. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.005 · Cited by 67
Harrington, B. K., Gardner, H. L., Izumi, R. E., Hamdy, A., Rothbaum, W. M., Coombes, K. R., Covey, T. M., Kaptein, A., Gulrajani, M., van Lith, B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159607 · Cited by 65
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site
Fabbro, D., Manley, P. W., Jahnke, W., Liebetanz, J., Szyttenholm, A., Fendrich, G., Strauss, A., Zhang, J., Gray, N. S., Adrián, F., et al. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.009 · Cited by 64
Jacus, M. O., Daryani, V. M., Harstead, K. E., Patel, Y. T., Throm, S. L., & Stewart, C. F. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0319-6 · Cited by 63
Abstract 1320: Preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor
Liu, X., Zhang, X., Yang, L., Tian, X., Dong, T., Ding, C. Z., Hu, L., Wu, L., Zhao, L., Mao, J. J. J., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-1320 · Cited by 63
Machida, Y., Nakagawa, M., Matsunaga, H., Yamaguchi, M., Ogawara, Y., Shima, Y., Yamagata, K., Katsumoto, T., Hattori, A., Itoh, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1349 · Cited by 62
New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons
Wang, L., Guillen, V. S., Sharma, N., Flessa, K., Min, J., Carlson, K. E., Toy, W., Braqi, S., Katzenellenbogen, B. S., Katzenellenbogen, J. A., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00106 · Cited by 61
Abdallah, S. M.-B., & Wong, A. N. M. (2018) · Current Oncology · doi:10.3747/co.25.3733 · Cited by 61
Hu, S., Xie, G., Zhang, D. X., Davis, C. B., Long, W. S., Hu, Y., Wang, F., Kang, X., Tan, F., Ding, L., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.067 · Cited by 60
Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier
Summerfield, S. G., Zhang, Y., & Liu, H. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232447 · Cited by 60
Sabari, J. K., Santini, F. C., Schram, A. M., Bergagnini, I., Chen, R., Mrad, C., Lai, W. V., Arbour, K. C., & Drilon, A. E. D. C. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s109295 · Cited by 60
Kirouac, D. C., Schaefer, G., Chan, J., Merchant, M., Orr, C., Huang, S.-M. A., Moffat, J., Liu, L., Gadkar, K., & Ramanujan, S. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0016-1 · Cited by 60
Hsu, C.-L., Liu, J.-S., Wu, P.-L., Guan, H., Chen, Y., Lin, A.-C., Ting, H., Pang, S., Yeh, S.-D., Ma, W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.009 · Cited by 58
Ma, L., Boucher, J. I., Paulsen, J. L., Matuszewski, S., Eide, C. A., Ou, J., Eickelberg, G., Press, R. D., Zhu, L. J., Druker, B. J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708268114 · Cited by 57
Sehgal, K., Patell, R. D., Rangachari, D., & Costa, D. B. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.08.11 · Cited by 57
The Energy Landscape Analysis of Cancer Mutations in Protein Kinases
Dixit, A., & Verkhivker, G. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026071 · Cited by 56
Yin, L., Li, H., Liu, W., Yao, Z., Cheng, Z., Zhang, H., & Zou, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.003 · Cited by 54
Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor
Kim, T. S., Cavnar, M. J., Cohen, N. A., Sorenson, E. C., Greer, J. B., Seifert, A. M., Crawley, M. H., Green, B. L., Popow, R., Pillarsetty, N., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3033 · Cited by 53
Emerging findings into molecular mechanism of brain metastasis
Ni, W., Chen, W., & Lu, Y. (2018) · Cancer Medicine · doi:10.1002/cam4.1667 · Cited by 53
Petrelli, F., Lazzari, C., Ardito, R., Borgonovo, K., Bulotta, A., Conti, B., Cabiddu, M., Capitanio, J. F., Brighenti, M., Ghilardi, M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201425 · Cited by 52
Munakata, W., Ando, K., Hatake, K., Fukuhara, N., Kinoshita, T., Fukuhara, S., Shirasugi, Y., Yokoyama, M., Ichikawa, S., Ohmachi, K., et al. (2019) · Cancer Science · doi:10.1111/cas.13983 · Cited by 51
Mian, A. A., Schull, M., Zhao, Z., et al. (2009) · Leukemia · doi:10.1038/leu.2009.69 · Cited by 50
Zhao, J., Zou, M., Lv, J., Han, Y., Wang, G., & Wang, G. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s170358 · Cited by 49
Tsang, R. Y., Sadeghi, S., & Finn, R. S. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s3783 · Cited by 48
Gruber, F., Hjorth‐Hansen, H., Mikkola, I., Stenke, L., & Johansen, T. (2006) · Leukemia · doi:10.1038/sj.leu.2404400 · Cited by 46
A reality check of the accelerated approval of immune-checkpoint inhibitors
Gill, J., & Prasad, V. K. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0260-y · Cited by 43
Mapping the Pathways of Resistance to Targeted Therapies
Wood, K. C. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1248 · Cited by 42
Leverson, J. D., & Cojocari, D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00458 · Cited by 42
Chen, S., Yu, L., Feng, Z., & Wang, M. (2019) · BMC Cancer · doi:10.1186/s12885-019-6132-0 · Cited by 41
Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors
Kinoshita, K., Ono, Y., Emura, T., Asoh, K., Furuichi, N., Ito, T., Kawada, H., Tanaka, S., Morikami, K., Tsukaguchi, T., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.020 · Cited by 40
Drug persistence – From antibiotics to cancer therapies
Kochanowski, K., Morinishi, L. S., Altschuler, S. J., & Wu, L. F. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.03.003 · Cited by 39
Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor
Chan, B. K., Hanan, E. J., Bowman, K. K., Bryan, M. C., Burdick, D. J., Chan, E. W., Chen, Y., Clausen, S., Vega, T. D., Dotson, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00995 · Cited by 38
Aronchik, I., Dai, Y., Labenski, M., Barnes, C., Jones, T., Qiao, L., Beebe, L., Malek, M., Elis, W., Shi, T., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0554 · Cited by 37
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
Santarpía, M., Daffinà, M. G., D’Aveni, A., Marabello, G., Liguori, A., Giovannetti, E., Karachaliou, N., Cao, M. G., Rosell, R., & Altavilla, G. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s113500 · Cited by 36
Vavalà, T., & Novello, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918789364 · Cited by 36
Epps, H. L. V. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.2013fta · Cited by 32
Kinact: a computational approach for predicting activating missense mutations in protein kinases
Rodrigues, C. H., Ascher, D. B., & Pires, D. E. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky375 · Cited by 31
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer
Passiglia, F., Caparica, R., Giovannetti, E., Giallombardo, M., Listì, A., Diana, P., Cirrincione, G., Caglevic, C., Raez, L. E., Russo, A. D., et al. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1152261 · Cited by 30
Tadesse, S., Mekonnen, L. B., Tomusange, K., Yu, M., Islam, S., Bykovska, N., Noll, B. D., Zhu, G., Li, P., Lam, F., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13974 · Cited by 29
Oh, D. K., Ji, W., Kim, W. S., Choi, C., Yoon, S., Rho, J. K., & Lee, J. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210225 · Cited by 29
Tsurutani, J., Park, H., Doi, T., Modi, S., Takahashi, S., Nakagawa, K., Krop, I. E., Waqar, S. N., Yoh, K., Li, B., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.244 · Cited by 27
Rodon, J. A., Gray, N. S., Mok, T. S. K., & Gainor, J. F. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_242209 · Cited by 27
Kaserer, T., & Blagg, J. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.07.013 · Cited by 24
Diverse mechanisms of PARP inhibitor resistance in ovarian cancer
Wakefield, M. J., Nesic, K., Kondrashova, O., & Scott, C. L. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.08.002 · Cited by 24
Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
Facchinetti, F., & Friboulet, L. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s190786 · Cited by 23
Bennett, G. S., Harrison, H., Campbell, S., Teufel, D. P., Langford, G., Watt, A., & Bonny, C. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32642-9 · Cited by 20
Wu, Y., Wang, B., Wang, J., Qi, S., Zou, F., Qi, Z., Liu, F., Liu, Q., Chen, C., Hu, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00280 · Cited by 20
Liu, X., Wang, B., Chen, C., Qi, Z., Zou, F., Wang, J., Hu, C., Wang, A., Ge, J., Liu, Q., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00176 · Cited by 18
Razavi, P., dos Anjos, C. H., Brown, D. N., Li, Q., Ping, C., Herbert, J., Colon, J., Liu, D., Mao, M., Norton, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.1009 · Cited by 17
Tarantelli, C., Zhang, L., Curti, E., Gaudio, E., Spriano, F., Priebe, V., Cascione, L., Arribas, A. J., Zucca, E., Rossi, D., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.214759 · Cited by 16
Strategies for Overcoming EGFR Resistance in the Treatment of Advanced-Stage NSCLC
Lovly, C. M., & Horn, L. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0204-6 · Cited by 15
Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases
Lockney, N. A., & Wu, A. J.-C. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.02.05 · Cited by 13
Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT
Kaitsiotou, H., Keul, M., Hardick, J., Mühlenberg, T., Ketzer, J., Ehrt, C., Krüll, J., Medda, F., Koch, O., Giordanetto, F., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00841 · Cited by 13
Heydt, C., Kumm, N., Fassunke, J., Künstlinger, H., Ihle, M. A., Scheel, A. H., Schildhaus, H., Haller, F., Büttner, R., Odenthal, M., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1311-0 · Cited by 8
Brigatinib effective in ALK-positive non-small-cell lung cancer
Das, M. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30342-x · Cited by 8
Race for undruggable KRAS speeds up
(2019) · Nature Biotechnology · doi:10.1038/s41587-019-0312-y · Cited by 8
Glass, G. E. (2014) · Indian Journal of Plastic Surgery · doi:10.4103/0970-0358.146619 · Cited by 5
Carlo, E. D., Savio, M. C. D., Polesel, J., Ros, V. D., Berto, E., Santarossa, S., Chimienti, E., Fratino, L., & Bearz, A. (2018) · Oncotarget · doi:10.18632/oncotarget.24573 · Cited by 4
Linghu, X., Wong, N. W. Y., Blake, J. F., Gaudino, J. J., & Moffat, J. G. (2018) · ACS symposium series · doi:10.1021/bk-2018-1307.ch001 · Cited by 4
Martin, E. C., Aarons, L. J., & Yates, J. W. T. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3630-8 · Cited by 3
Cited by
Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q. B., Pecho, R. D. C., Jayasankar, N., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01865-0 · Cited by 1,062
Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs)
Cooper, B. M., Iegre, J., O' Donovan, D. H., Ölwegård Halvarsson, M., & Spring, D. R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00556h · Cited by 414
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 369
Truskewycz, A., Yin, H., Halberg, N., Lai, D. T. H., Ball, A. S., Truong, V. K., Rybicka, A. M., & Cole, I. (2022) · Small · doi:10.1002/smll.202106342 · Cited by 296
Feng, L., Li, C., Liu, L., Wang, Z., Chen, Z., Yu, J., Ji, W., Jiang, G., Zhang, P., Wang, J., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c10019 · Cited by 268
Metadata
- Authors
- Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-07-21
- Volume
- 121
- Issue
- 6
- Pages
- 3297-3351
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W3043934334
- Cited by
- 445
- References
- 339
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.